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Abstract
Predictive tests for estimating the risk of developing late-stage neovascular age-related macular degeneration
(AMD) are subject to unique challenges. AMD prevalence increases with age, clinical phenotypes are hetero-
geneous and control collections are prone to high false-negative rates, as many control subjects are likely to
develop disease with advancing age. Risk prediction tests have been presented previously, using up to ten genetic
markers and a range of self-reported non-genetic variables such as body mass index (BMI) and smoking history.
In order to maximise the accuracy of prediction for mainstream genetic testing, we sought to derive a test com-
parable in performance to earlier testing models but based purely on genetic markers, which are static through
life and not subject to misreporting. We report a multicentre assessment of a larger panel of single nucleotide
polymorphisms (SNPs) than previously analysed, to improve further the classification performance of a predictive
test to estimate the risk of developing choroidal neovascular (CNV) disease. We developed a predictive model
based solely on genetic markers and avoided inclusion of self-reported variables (eg smoking history) or
non-static factors (BMI, education status) that might otherwise introduce inaccuracies in calculating individual risk
estimates. We describe the performance of a test panel comprising 13 SNPs genotyped across a consolidated
collection of four patient cohorts obtained from academic centres deemed appropriate for pooling. We report
on predictive effect sizes and their classification performance. By incorporating multiple cohorts of homogeneous
ethnic origin, we obtained .80 per cent power to detect differences in genetic variants observed between cases
and controls. We focused our study on CNV, a subtype of advanced AMD associated with a severe and poten-
tially treatable form of the disease. Lastly, we followed a two-stage strategy involving both test model develop-
ment and test model validation to present estimates of classification performance anticipated in the larger clinical
setting. The model contained nine SNPs tagging variants in the regulators of complement activation (RCA) locus
spanning the complement factor H (CFH), complement factor H-related 4 (CFHR4), complement factor H-related
5 (CFHR5) and coagulation factor XIII B subunit (F13B) genes; the four remaining SNPs targeted polymorphisms
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in the complement component 2 (C2), complement factor B (CFB), complement component 3 (C3) and age-
related maculopathy susceptibility protein 2 (ARMS2) genes. The pooled sample size (1,132 CNV cases, 822 con-
trols) allowed for both model development and model validation to confirm the accuracy of risk prediction. At
the validation stage, our test model yielded 82 per cent sensitivity and 63 per cent specificity, comparable with
metrics reported with earlier testing models that included environmental risk factors. Our test had an area
under the curve of 0.80, reflecting a modest improvement compared with tests reported with fewer SNPs.
Keywords: age-related macular degeneration (AMD), choroidal neovascularisation (CNV), complement factor H (CFH),
genetic testing
Introduction
Many diseases of ageing characterised by complex
inheritance patterns are progressive; the individual
may be asymptomatic in the early stages. One of
these diseases, age-related macular degeneration
(AMD), is the most common cause of visual
impairment and the leading cause of blindness in
the elderly population in the developed world.
The prevalence of AMD increases with advancing
age in all populations studied. Thus, in developed
nations such as the USA, UK, Canada and
Australia, with increasingly aged populations, the
condition affects a progressively larger segment of
the population and has become a major public
health issue. Early- or late-stage AMD is present
in 15 per cent of individuals over the age of 60
years.1 It is estimated that there are currently 9.1
million patients in the USA with AMD, of which
1.7 million suffer with the vision-threatening late-
stage complications of choroidal neovascularisation
(CNV) or geographic atrophy.1 Moreover, it is
predicted that the number of cases of early AMD
will increase to 17.8 million by 2050 and, if
untreated, cases of late-stage blinding AMD will
increase to 3.8 million.1 It has been determined
that vision loss from AMD decreases quality of life
by 60 per cent, similar to the experience of
dealing with a stroke that requires intensive
nursing care.2
The clinical presentation and natural course of
AMD are highly variable. The disease may present
as early as the fifth decade of life or as late as the
ninth decade. The clinical symptoms of AMD
range from no visual disturbances in early disease to
profound loss of central vision in the advanced late
stages of the disease. Some patients never progress
beyond early AMD; however, in 10–15 per cent of
Caucasian patients with early-stage disease, the
condition progresses to an exudative neovascular
(or ‘wet’ form) or geographic atrophic (or ‘dry’
form) AMD, which threatens vision. The pheno-
type is characterised by development of subretinal
choroidal neovascular complexes, haemorrhage and
fibrosis and is typically associated with severe
central vision loss.3,4
AMD has been one of the success stories of the
genome revolution and is probably one of the best
characterised of the complex trait diseases in terms
of genetic predisposition (for reviews, see Allikmets
and Dean5 and Swaroop et al.6). Besides age, genetic
background is the most significant non-modifiable
risk factor for all stages of AMD, while smoking is
the most significant modifiable risk factor.7,8 Initial
groundbreaking studies established that loci on
chromosomes (Chr) 1 and 10 — in particular the
complement factor H (CFH) and the age-related
maculopathy susceptibility protein 2 (ARMS2)/high
temperature requirement factor A1 (HTRA1) genes,
respectively — are significantly associated with
AMD risk and protection in populations of various
ethnicities.9–19 Although the specific role(s) of the
Chr 10 genes in AMD pathobiology has not yet
been elucidated, the role of the alternative comp-
lement pathway, where CFH functions as a major
fluid-phase regulator, is well established (see
Anderson et al.20,21 Gehrs et al.22,23 Hageman
et al.24,25 and Mullins et al.26 for overviews). Early
pathobiological investigations showed dysregulation
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of the complement cascade to be a critical early pre-
disposing step in the development of AMD. This
spurred the discovery of the association of CFH
variants with AMD risk. Subsequent genetic investi-
gations revealed additional associations between
AMD and risk/protective variants in various comp-
lement pathway-associated genes, including comp-
lement component 2 (C2), complement factor B
(CFB), complement component 3 (C3), comp-
lement factor H-related 1 and 3 (CFHR1 and
CFHR3) and complement factor I (CFI).21,27–38
Using a genome-wide association approach, a
handful of additional AMD-associated loci have
been reported recently; these appear to be modestly
associated with AMD risk and will probably require
replication in additional cohorts to establish their
role in AMD pathogenesis39,40 (see also Gehrs
et al.23 for a review).
A prerequisite for a new era in genetic testing
and diagnosis for AMD is a robust test that accu-
rately captures the impact of consistently replicated
AMD risk variants in predicting the risk of devel-
oping CNV. Patients with CNV represent an
important segment of the AMD population that
would benefit from early diagnosis, given the
current availability of an effective therapeutic inter-
vention. Jakobsdottir and coworkers41 recently con-
cluded that the diagnostic value of three variants in
the CFH, ARMS2/HTRA1 and C2 genes was not
sufficient to discriminate between individuals with
and without AMD because of the relatively low
sensitivity and specificity of the combined test
panel, in combination with the relatively low
prevalence of late-stage disease in the general popu-
lation. They applied a three single nucleotide poly-
morphism (SNP) test to their cohort of 640
late-stage AMD cases and 142 controls to demon-
strate a clinical sensitivity of 74 per cent and a
specificity of 69 per cent, with a reported area
under the curve (AUC) — a measure of how well
a test or classifier can distinguish between cases and
controls — of 0.79. Perfect test discrimination
would yield an AUC of 1.0. Jakobsdottir and col-
leagues also reported that the positive predictive
value (PPV) of the same test is affected by different
values of disease prevalence reflective of age.
Seddon and colleagues42 evaluated six AMD
risk-associated variants in CFH, ARMS2/HTRA1,
C2, CFB and C3 with the goal of developing a
predictive risk test for late-stage AMD. After con-
trolling for smoking, body mass index (BMI) and
vitamin intake, they demonstrated a strong associ-
ation between these six risk variants and the preva-
lence of late-stage AMD, as well as progression to
late-stage disease in early AMD patients. The pro-
gression test described by Seddon et al.,42 which
included genetic, environmental and treatment
variables, achieved a performance of 83 per cent
sensitivity and 68 per cent specificity, with a
reported AUC of 0.82. McKay and co-workers43
extended this test further, proposing a ten-SNP
panel plus smoking history to predict the risk of
late-stage AMD. Their inclusion of six CFH SNPs
was designed to capture the haplotype structure of
the locus, to improve classification performance.
Zanke and colleagues44 have presented risk scores
by selecting marker-specific odds ratios from dispa-
rate sources and multiplying them together. As the
latter approach does not benefit from a joint assess-
ment of the markers (as they perform in combi-
nation), it may overestimate an individual’s risk of
disease.
In this study, we assessed the accuracy of a panel
of 13 SNPs without consideration of environ-
mental risk factors such as smoking or BMI, to
predict the risk of developing CNV in Caucasian
individuals 60 years of age and older. Test model
development and validation were designed to
evaluate these variants in eight AMD-associated
genes (CFH, complement factor H-related 4
(CFHR4), complement factor H-related 5
(CFHR5) and coagulation factor XIII B subunit
(F13B) located within the regulators of comp-
lement activation (RCA) region on Chr 1, C2 and
CFB on Chr 6, C3 on Chr 19 and ARMS2 on
Chr 10. The panel of 13 SNPs was tested in well-
established case–control and sibling pair cohorts
from five academic centres (University of Iowa,
University of Utah, Columbia University, Harvard
University and Melbourne University) to validate
the accuracy of the predictive test and to estimate
an individual’s genetic risk for developing late-stage
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CNV. Most of the disease-associated genetic var-
iants in CFH, ARMS2, C2, CFB and C3 were
selected based on prior replication in multiple
studies and performance in resolving the most fre-
quent CFH haplotype combinations. Additional
SNPs detecting variants in CFHR4 (rs1409153),
CFHR5 (rs10922153 and rs1750311) and F13B
(rs698859 and rs2990510) tagged novel extended
haplotypes spanning the CFH-to-F13B region and
were included to maximise the resolution of clini-
cally relevant subtypes suspected to have high
association with disease.45 The additional SNPs
were selected to distinguish the novel haplotypes
from the more prevalent haplotypes reported pre-
viously (H1, H2, H3, H4).13 The performance
metrics obtained during the clinical validation of
the 13-SNP panel were used as a benchmark to
compare with other published AMD-predictive
tests directed at estimating an individual’s risk of
developing late-stage disease. Since the inclusion of
several established non-genetic factors (eg smoking)
was highly variable across the published tests, the
focus of this investigation was to isolate the contri-
bution conferred by genetic variation alone, in
order to determine whether the more comprehen-
sive collection of SNPs could further improve pre-
diction accuracy. The methodology used in the
clinical validation of the 13-SNP test panel was
subsequently applied to two panels of markers32,42
that had been assessed previously and contained
variants that overlapped with the markers contained
within our 13 SNP panel. Both test panels were
evaluated in the large collective cohort by using a
validation step absent in prior publications. Testing
the two panels in a large collection of subjects
from different centres assembled from several inde-
pendent collections was designed to minimise the
introduction of selection bias inherent in a single
cohort study. Additionally, the use of an indepen-
dent validation sample was intended to aggressively
challenge the 13-SNP panel, to anticipate per-
formance metrics in a broader clinical setting more
accurately. Running the three test panels (three
SNPs, six SNPs and 13 SNPs) on the same
samples allowed for the comparison of perform-
ance metrics based exclusively on genetic variants.
Materials and methods
Subjects
Four well-characterised cohorts (Iowa,13,30
Boston,38 Columbia,13,30 and Melbourne46,47) and
one recently acquired, but as yet unreported,
cohort (Utah), together comprised 1,709 patients
diagnosed with CNV and 1,473 disease-free con-
trols (for which genotyping data were already avail-
able), were assessed (Table 1). All individuals
were of white European ancestry, 60 years of age
and older and matched for age. All patients had
given their consent and were enrolled under
Institutional Review Board-approved protocols.
The methods used in this study conformed to the
tenets of the Declaration of Helsinki (2000) of the
World Medical Association. Study subjects were
examined and photographed by trained ophthal-
mologists; fundus photographs were graded accord-
ing to published standardised classification systems.
The worst affected eye of each case was used for
classification purposes. All cohorts were case-
controlled, with the exception of the Boston
sib-pair cohort. Index patients in the Boston
cohort aged 60 years or older were included in the
analyses and had CNV, (as defined by subretinal
haemorrhage, fibrosis or fluorescein angiographic
presence of neovascularisation documented at the
time of, or prior to, enrolment in the study) in at
least one eye. The unaffected siblings had normal
maculae at an age older than that at which the
index patient was first diagnosed with CNV, as
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previously described.38 The Utah case–control
cohort was recently ascertained at the John
A. Moran Eye Center, University of Utah, in Salt
Lake City, Utah, USA, in a fashion identical to that
of the Iowa cohort.
Markers
Thirteen SNPs, spanning four physically separate
genomic loci, were genotyped in all five cohorts
(Table 2). One locus spans the CFH, CFHR4,
CFHR5 and F13B genes and comprises nine
SNPs; the second consists of two SNPs, one each
in C2 and CFB; the third consists of a single
SNP in C3; and the fourth consists of a single
SNP in ARMS2. One of the CFH SNPs
(rs12144939) included in the panel tags the
CFHR3/1 deletion. The 13 SNPs were selected
on the basis of the following characteristics: prior
published replication, magnitude of estimated
effect size and power to resolve clinically relevant
haplotypes (CFH).5–19
Statistical methods
Previous analyses of each cohort involved standard
quality checks and exclusions. Prior to analysis, the
consistency of the assignment of the DNA strand
used to detect the SNPs was assessed for all avail-
able datasets and any inconsistencies resolved. The
percentage of missing data and the genotype fre-
quencies were calculated and tabulated for each
SNP, both by study (data not shown) and overall
(Table 3). No SNPs showed significant deviation
from Hardy–Weinberg equilibrium in the control
population (P . 0.05).
In order to determine the appropriateness of
pooling the available cohorts, a chi-squared test of
homogeneity of allele frequency was applied to
compare frequencies across cohorts. Cohorts or sub-
cohorts found to be a source of a departure
from homogeneity of allele frequency (chi square P ,
0.001) were excluded from the main analysis.
Individuals with CNV were compared with
the control group of subjects with no recorded
disease. Genotypic multivariate and univariate






rs1061170 1 194,925,860 196,659,237 CFH (exon 9)
rs2274700 1 194,949,570 196,682,947 CFH (exon 10)
rs403846 1 194,963,360 196,696,737 CFH (intron 14)
rs12144939 1 194,965,568 196,698,945 CFH (intron 15)
rs1409153 1 195,146,628 196,880,005 CFHR4
rs1750311 1 195,220,848 196,954,225 CFHR5
rs10922153 1 195,245,238 196,978,615 CFHR5
rs698859 1 195,274,988 197,008,365 F13B
rs2990510 1 195,287,281 197,020,658 F13B
rs9332739 6 32,011,783 31,903,804 C2
rs641153 6 32,022,159 31,914,180 CFB
rs10490924 10 124,204,438 124,214,448 LOC387155 / ARMS2
rs2230199 19 6,669,387 6,718,387 C3
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unconditional logistic regression analyses were
performed to evaluate the relationships between
risk of CNV and the additively coded genotypes
(Supplementary Analysis 1). Odds ratios (ORs)
and 95 per cent confidence intervals (CIs) were
calculated. The full 13-SNP panel was
evaluated both with and without demographic
factors of age and sex. Backward elimination was
performed on the training set using a threshold of
P , 0.05.
Table 3. Homogeneity of variance
Counts (row frequency)
Cohort rs10490924 Code 5 CNTL Total
GG GT TT
Boston 101 71 26 198
51.01% 35.86% 13.13% 100.00%
Columbia 218 136 14 368
59.24% 36.96% 3.80% 100.00%
Iowa 230 117 13 360
63.89% 32.50% 3.61% 100.00%
Melbourne 277 145 16 438
63.24% 33.11% 3.65% 100.00%
Utah 62 39 0 101
61.39% 38.61% 0.00% 100.00%
Total 888 508 69 1,465
Counts (row frequency)
Cohort rs403846 Code ¼ CNTL Total
AA AG GG
Boston 41 102 55 198
20.71% 51.52% 27.78% 100.00%
Columbia 32 164 165 361
8.86% 45.43% 45.71% 100.00%
Iowa 68 179 118 365
18.63% 49.04% 32.33% 100.00%
Melbourne 71 229 137 437
16.25% 52.40% 31.35% 100.00%
Utah 13 61 27 101
12.87% 60.40% 26.73% 100.00%




Cohort rs1409153 Code 5 CNTL Total
AA AG GG
Boston 67 97 34 198
33.84% 48.99% 17.17% 100.00%
Columbia 177 161 29 367
48.23% 43.87% 7.90% 100.00%
Iowa 128 177 60 365
35.07% 48.49% 16.44% 100.00%
Melbourne 150 226 63 439
34.17% 51.48% 14.35% 100.00%
Utah 31 60 10 101
30.69% 59.41% 9.90% 100.00%
Total 553 721 196 1,470
Counts (row frequency)
Cohort rs10922153 Code ¼ CNTL Total
GG GT TT
Boston 53 102 43 198
26.77% 51.52% 21.72% 100.00%
Columbia 55 181 122 358
15.36% 50.56% 34.08% 100.00%
Iowa 99 172 94 365
27.12% 47.12% 25.75% 100.00%
Melbourne 94 234 113 441
21.32% 53.06% 25.62% 100.00%
Utah 20 59 21 100
20.00% 59.00% 21.00% 100.00%
Total 321 748 393 1,462
Continued
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Two published test models containing, respect-
ively, three and six SNPs, and a nine-SNP model
generated from backward elimination, were com-
pared with the 13-SNP panel in terms of AUC in
training and independent validation. In the event
that an SNP was not present in the 13-SNP panel,
a SNP with demonstrated linkage disequilibrium
was used as a surrogate.
Training of classifiers was performed using 500
cases and 500 controls balanced by age and sex and
randomly selected from the whole cohort. The
remaining 322 controls and 632 cases were used
for validation. In both analyses, ten-fold cross-
validation was applied.50 The predicted probability
of affliction for each subject was calculated by
applying the inverse-logit function; sensitivity,
specificity and AUC were derived to assess classifi-
cation performance.
A risk score for CNV was calculated as follows:
Sj ¼ interceptþ
P13
i¼1 bi Xi where Sj is the risk
score for subject j and bi is the adjusted log-odds
ratio for Xi, the additively coded genotype at
marker i. The probability of risk for subject j was
calculated as pj ¼ exp(Sj)/[1 þ exp(Sj)].
The optimal classification threshold was deter-
mined on the basis of accuracy, defined as the pro-
portion of correct predictions observed in cases and
controls. Different levels of prevalence, reflecting
age-specific differences, were considered. The
accuracy in the validation set was determined, and
positive and negative predictive values were calcu-
lated. Calibration was assessed graphically as histo-
grams showing disease incidence at different levels
of predicted risk for controls and cases.
The area under the receiver operating character-
istic (ROC) curve and CIs were estimated using
SAS Macro %ROC.51 In addition, c-statistics and
CIs were calculated for the training, tenfold cross-
validation and validation datasets.52,53
All analyses were conducted using SAS 9.1.52
Results
The average ages (+ standard deviation [SD]) of
cases and controls among all cohorts were 76.4
(+7.3) and 76.5 (+7.1) years, respectively, and
the differences were not significant (p ¼ 0.86). Age
matching was applied during cohort ascertainment.
The chi-square test was used to assess homogeneity
of allele frequency across cohorts. Frequencies of
markers rs10490924, rs403846, rs1409153,
Table 3. Continued
Counts (row frequency)
Cohort rs403846 Code 5 CNV Total
AA AG GG
Boston 141 149 48 338
41.72% 44.08% 14.20% 100.00%
Columbia 148 255 116 519
28.52% 49.13% 22.35% 100.00%
Iowa 110 137 37 284
38.73% 48.24% 13.03% 100.00%
Melbourne 179 218 74 471
38.00% 46.28% 15.71% 100.00%
Utah 33 46 14 93
35.48% 49.46% 15.05% 100.00%
Total 611 805 289 1,705
Counts (row frequency)
Cohort rs698859 Code ¼ CNV Total
AA AG GG
Boston 85 147 105 337
25.22% 43.62% 31.16% 100.00%
Columbia 78 238 205 521
14.97% 45.68% 39.35% 100.00%
Iowa 69 136 79 284
24.30% 47.89% 27.82% 100.00%
Melbourne 76 233 163 472
16.10% 49.36% 34.53% 100.00%
Utah 19 49 25 93
20.43% 52.69% 26.88% 100.00%
Total 327 803 577 1,707
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Age (+SD) 76.4 (7.3) 76.5 (7.1) 1.001 (0.989–1.013) 0.87 0.50
Sex F 451 (55%) 696 (61%) 1.313 (1.094–1.576) 0.0034 0.53
M 371 (45%) 436 (39%)
rs10490924 GG 520 (63.3%) 340 (30%) 0.061 (0.04–0.093) , 0.0001 0.70
GT 269 (32.7%) 505 (44.6%) 0.175 (0.114–0.268)
TT 26 (3.2%) 279 (24.6%)
(blank) 7 (0.9%) 8 (0.7%)
rs1061170 CC 114 (13.9%) 394 (34.8%) 5.184 (3.934–6.831) , 0.0001 0.65
CT 408 (49.6%) 535 (47.3%) 1.967 (1.575–2.456)
TT 294 (35.8%) 196 (17.3%)
(blank) 6 (0.7%) 7 (0.6%)
rs10922153 GG 189 (23%) 498 (44%) 4.819 (3.64–6.382) , 0.0001 0.64
GT 418 (50.9%) 515 (45.5%) 2.254 (1.738–2.922)
TT 214 (26%) 117 (10.3%)
(blank) 1 (0.1%) 2 (0.2%)
rs12144939 GG 504 (61.3%) 930 (82.2%) 7.996 (3.842–16.639) , 0.0001 0.61
GT 275 (33.5%) 192 (17%) 3.025 (1.432–6.391)
TT 39 (4.7%) 9 (0.8%)
(blank) 4 (0.5%) 1 (0.1%)
rs1409153 AA 282 (34.3%) 192 (17%) 0.203 (0.154–0.267) , 0.0001 0.64
AG 420 (51.1%) 539 (47.6%) 0.382 (0.3–0.487)
GG 118 (14.4%) 396 (35%)
(blank) 2 (0.2%) 5 (0.4%)
rs1750311 AA 95 (11.6%) 53 (4.7%) 0.289 (0.202–0.415) , 0.0001 0.59
AC 373 (45.4%) 411 (36.3%) 0.572 (0.472–0.692)
CC 346 (42.1%) 667 (58.9%)
(blank) 8 (1%) 1 (0.1%)
rs2230199 CC 521 (63.4%) 621 (54.9%) 0.447 (0.289–0.691) , 0.0001 0.55
CG 267 (32.5%) 428 (37.8%) 0.601 (0.385–0.94)
GG 30 (3.6%) 80 (7.1%)
(blank) 4 (0.5%) 3 (0.3%)
Continued
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rs698859, rs403846 and rs10922153 were signifi-
cantly different (P , 0.001) across cohorts. The fre-
quencies of four markers — rs10490924, (ARMS2)
rs403846, (CFH) rs1409153 (CFHR4) and
rs10922153 (CFHR5) — in the control population
and two markers — rs698859 (F13B) and rs403846
(CFH) — in the CNV population were unbalanced
(Table 3). Removal of the Columbia University
cohort eliminated four of the five deviations,
leaving only one SNP (rs10490924) outstanding in
the Boston control population. The Boston con-
trols and Columbia cases and controls were
excluded from the main analyses based on these
observations. The remaining study population con-
tained 1,132 CNV cases and 822 controls. For the











rs2274700 AA 144 (17.5%) 48 (4.2%) 0.128 (0.09–0.183) , 0.0001 0.66
AG 403 (49%) 378 (33.4%) 0.361 (0.296–0.441)
GG 268 (32.6%) 696 (61.5%)
(blank) 7 (0.9%) 10 (0.9%)
rs2990510 GG 78 (9.5%) 183 (16.2%) 2.082 (1.541–2.813) , 0.0001 0.55
GT 389 (47.3%) 544 (48.1%) 1.241 (1.023–1.506)
TT 355 (43.2%) 400 (35.3%)
(blank) (0%) 5 (0.4%)
rs403846 AA 137 (16.7%) 445 (39.3%) 5.059 (3.848–6.652) , 0.0001 0.65
AG 424 (51.6%) 521 (46%) 1.914 (1.515–2.418)
GG 257 (31.3%) 165 (14.6%)
(blank) 4 (0.5%) 1 (0.1%)
rs641153 CC 644 (78.3%) 984 (86.9%) 2.674 (1.115–6.41) , 0.0001 0.55
CT 159 (19.3%) 129 (11.4%) 1.42 (0.578–3.489)
TT 14 (1.7%) 8 (0.7%)
(blank) 5 (0.6%) 11 (1%)
rs698859 AA 120 (14.6%) 235 (20.8%) 1.644 (1.257–2.15) 0.0012 0.54
AG 403 (49%) 541 (47.8%) 1.127 (0.922–1.378)
GG 298 (36.3%) 355 (31.4%)
(blank) 1 (0.1%) 1 (0.1%)
rs9332739 CC 2 (0.2%) 1 (0.1%) 0.348 (0.032–3.85) 0.0022 0.52
CG 72 (8.8%) 55 (4.9%) 0.532 (0.37–0.766)
GG 745 (90.6%) 1069 (94.4%)
(blank) 3 (0.4%) 7 (0.6%)
CI, confidence interval
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the differences were not pursued but could be eval-
uated in the future by performing structure analysis
to identify potential causes for the observed
differences.
Table 4 shows unadjusted association test results
between the demographic and genetic factors and
the risk of CNV. All factors except age were associ-
ated with risk of CNV. The c-statistic column
shows the ability of a genetic factor to predict
CNV risk. SNPs rs10490924, rs1061170, rs403846
and rs2274700 had c-statistics 0.65.
Table 5 displays multivariate adjusted ORs that
were significantly associated with the risk of CNV,
using the additive genotype model applied to the
13-SNP panel. The ARMS2 variant rs10490924
was positively associated with risk of CNV (OR
4.279, 95 per cent CI 3.346–5.472, p , 0.0001).
The performance of the 13-SNP panel to predict
CNV relative to the control population was evalu-
ated using tenfold cross-validation and an
independent dataset. Independent datasets were
scored using model parameters displayed in Table 5.
Table 6 shows the AUC evaluated for training
(AUC 0.82 [0.79–0.85]), tenfold cross-validation
(AUC 0.81 [0.79–0.84]) and validation (AUC 0.79
[0.77–0.83]). The c-statistics results were identical
to AUC. These data show that the difference in
Table 5. Calculation of choroidal neovascular disease risk score: S ¼ intercept þ
P
i¼1









Intercept 0.7851 0.1885 1 — — — —
rs10490924 1.4537 ,0.0001 GG ¼ 0,GT ¼ 1,TT ¼ 2 4.279 3.346 5.472 ,0.0001
rs1061170 20.7687 0.0105 CT ¼ 1,CC ¼ 0,TT ¼ 2 0.464 0.257 0.835 0.0105
rs10922153 20.6018 0.1129 GT ¼ 1,GG ¼ 0,TT ¼ 2 0.548 0.26 1.153 0.1129
rs12144939 20.1974 0.4375 GG ¼ 0,GT ¼ 1,TT ¼ 2 0.821 0.499 1.351 0.4375
rs1409153 20.1595 0.5665 AG ¼ 1,GG ¼ 0,AA ¼ 2 0.853 0.494 1.471 0.5665
rs1750311 20.1316 0.6834 CC ¼ 0,AC ¼ 1,AA ¼ 2 0.877 0.466 1.65 0.6834
rs2230199 0.428 0.0009 CC ¼ 0,CG ¼ 1,GG ¼ 2 1.534 1.192 1.975 0.0009
rs2274700 20.7954 0.0002 GG ¼ 0,AG ¼ 1,AA ¼ 2 0.451 0.296 0.689 0.0002
rs2990510 20.4596 0.1358 GT ¼ 1,TT ¼ 0,GG ¼ 2 0.632 0.345 1.155 0.1358
rs403846 0.8131 0.0404 AG ¼ 1,AA ¼ 0,GG ¼ 2 2.255 1.036 4.906 0.0404
rs641153 20.8243 ,0.0001 CC ¼ 0,CT ¼ 1,TT ¼ 2 0.439 0.295 0.651 ,0.0001
rs698859 20.015 0.9559 AG ¼ 1,GG ¼ 0,AA ¼ 2 0.985 0.58 1.673 0.9559
rs9332739 20.9544 0.0027 GG ¼ 0,CG ¼ 1,CC ¼ 2 0.385 0.206 0.719 0.0027
a The probability of risk ¼ exp(risk score)/[1 þ exp(risk score)]
Table 6. Area under the curve for training, tenfold













467/482 0.81 0.01 0.79 0.84
Validation 322/632 0.80 0.02 0.77 0.83
SNP, single nucleotide polymorphism; CNV, choroidal neovascular; ROC, receiver
operating characteristic
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performance of the training and validation sets was
not significant (P , 0.05). There were no signifi-
cant differences between the AUC curves for the
training and validation datasets with demographic
factors (age, sex) added into the test model
(Table 7), presumably due to the balanced study
design.
The sensitivity and specificity of predictions were
calculated in an independent dataset using the test
panels in Table 5. The ROC curve is shown in
Figure 1. The probability of the risk of CNV was
plotted as histograms for controls and cases in the
independent dataset in Figure 2. It shows good sep-
aration between the two groups, with cases having







Training Age þ Sex þ 13 SNP 0.82 0.01 0.79–0.85
Training 13 SNP 0.82 0.01 0.79–0.85
Validation Age þ Sex þ 13 SNP 0.80 0.02 0.77–0.83
Validation 13 SNP 0.80 0.02 0.77–0.83
ROC, receiver operating characteristic; SNP, single nucleotide polymorphism
Figure 1. ROC curve for validation.
ROC, receiver operating characteristic
Figure 2. Probability of choroidal neovascular (CNV) disease, calculated for validation dataset using model described in Table 2. Red
bars represent controls and blue bars represent patients with CNV disease.
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Table 8. Classification table
Prob.
level












0.00 100.0 0.0 5.5 — 10.0 — 15.0 —
0.02 99.8 0.2 5.5 94.5 10.0 90.0 15.0 85.0
0.04 99.8 2.1 5.6 99.4 10.2 99.0 15.2 98.3
0.06 99.8 4.3 5.7 99.7 10.4 99.5 15.5 99.2
0.08 98.8 8.6 5.9 99.2 10.7 98.5 16.0 97.6
0.10 98.1 12.0 6.1 99.1 11.0 98.3 16.4 97.3
0.12 97.7 15.0 6.3 99.1 11.3 98.3 16.9 97.4
0.14 97.3 18.2 6.5 99.1 11.7 98.4 17.3 97.4
0.16 96.7 20.8 6.6 99.1 11.9 98.3 17.7 97.3
0.18 95.9 23.8 6.8 99.0 12.3 98.1 18.2 97.0
0.20 95.0 29.1 7.2 99.0 13.0 98.1 19.1 97.1
0.22 93.6 33.0 7.5 98.9 13.4 97.9 19.8 96.7
0.24 92.9 38.1 8.0 98.9 14.3 98.0 20.9 96.8
0.26 91.7 43.3 8.6 98.9 15.2 97.9 22.2 96.7
0.28 90.5 45.2 8.8 98.8 15.5 97.7 22.6 96.4
0.30 88.8 48.8 9.2 98.7 16.2 97.5 23.4 96.1
0.32 86.9 50.7 9.3 98.5 16.4 97.2 23.7 95.6
0.34 86.1 53.7 9.8 98.5 17.1 97.2 24.7 95.6
0.36 85.5 56.7 10.3 98.5 18.0 97.2 25.8 95.7
0.38 83.4 60.4 10.9 98.4 19.0 97.0 27.1 95.4
0.40 81.7 63.2 11.4 98.3 19.8 96.9 28.1 95.1
0.42 80.5 65.3 11.9 98.3 20.5 96.8 29.0 95.0
0.44 78.4 66.6 12.0 98.1 20.7 96.5 29.3 94.6
0.46 77.8 68.1 12.4 98.1 21.3 96.5 30.1 94.6
0.48 73.7 71.7 13.2 97.9 22.4 96.1 31.5 93.9
0.50 72.4 74.7 14.3 97.9 24.1 96.1 33.6 93.9
0.52 70.3 75.4 14.3 97.8 24.1 95.8 33.5 93.5
0.54 68.9 76.0 14.3 97.7 24.2 95.7 33.6 93.3
0.56 68.5 76.9 14.7 97.7 24.8 95.6 34.4 93.3
0.58 63.9 79.9 15.6 97.4 26.1 95.2 35.9 92.6
0.60 61.4 84.6 18.8 97.4 30.7 95.2 41.3 92.5
Continued
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a substantially higher probability of CNV, although
some overlap is present.
Accuracy, specificity, sensitivity, PPV and negative
predicted values (NPV) are shown in Table 8 as a
function of probability cut-off and three prevalence
values. A cut-off of 0.4 corresponds to the highest
accuracy (0.73), with a sensitivity of 0.82 and a speci-
ficity of 0.63. The PPV for 5.5 per cent, 10 per cent
and 15 per cent prevalence values were 0.11, 0.20
and 0.28, respectively. The NPVs were all above 0.95.
We compared several published predictive models
with our current 13-SNP panel (Table 9). The
differences in test performance were evaluated at
training and validation stages. The performance of
the 13-SNP panel was slightly better than that of the
next best test.41,42 Results from the nine-SNP panel
generated from the backwards elimination procedure
realised gains in genotyping efficiency, with four
fewer variants in the panel, while demonstrating
only slightly lower performance in terms of AUC.
Discussion
Although the incorporation of non-static and self-
reported variables is important in elucidating the
modifiable risk factors that contribute to disease,
their inclusion can degrade test performance in
















0.62 60.4 85.4 19.4 97.4 31.5 95.1 42.2 92.4
0.64 58.3 86.1 19.6 97.3 31.8 94.9 42.5 92.1
0.66 56.6 87.6 21.0 97.2 33.7 94.8 44.6 92.0
0.68 51.5 89.1 21.6 96.9 34.4 94.3 45.5 91.2
0.70 50.0 90.4 23.3 96.9 36.7 94.2 47.9 91.1
0.72 47.7 91.4 24.4 96.8 38.1 94.0 49.5 90.8
0.74 44.6 92.3 25.2 96.6 39.2 93.7 50.5 90.4
0.76 43.8 92.9 26.4 96.6 40.7 93.7 52.1 90.4
0.78 41.3 93.8 27.9 96.5 42.5 93.5 54.0 90.1
0.80 37.1 95.1 30.6 96.3 45.7 93.2 57.2 89.5
0.82 33.6 95.7 31.3 96.1 46.5 92.8 58.0 89.1
0.84 30.1 96.4 32.7 96.0 48.2 92.5 59.6 88.7
0.86 22.4 97.9 38.3 95.6 54.2 91.9 65.3 87.7
0.88 20.3 98.1 38.3 95.5 54.3 91.7 65.3 87.5
0.90 14.7 99.6 68.1 95.3 80.3 91.3 86.6 86.9
0.92 10.4 99.8 75.2 95.0 85.2 90.9 90.2 86.3
0.94 7.9 100.0 100.0 94.9 100.0 90.7 100.0 86.0
0.96 3.9 100.0 100.0 94.7 100.0 90.4 100.0 85.5
0.98 0.6 100.0 100.0 94.5 100.0 90.1 100.0 85.1
1.00 0.0 100.0 – 94.5 – 90.0 – 85.0
Prob., probability; PPV, positive predictive value; NPV, negative predictive value
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panel, subject to rigorous validation, which captures
the maximal genetic component should improve
classification performance and accuracy of reporting.
In line with these criteria, which are much stricter
than in a discovery cohort, the Boston cohort con-
trols and the Columbia cohort cases and controls
were not considered for the calculation of the model.
Possible explanations for the allele frequency devi-
ations in these cohorts include admixture, cryptic
population stratification, subtle differences in grading
criteria, cohort age range, concomitant illnesses or
medications, and should be explored further.
In order to compare performance across tests, a
ROC curve was generated for each prediction panel
to evaluate the AUC. By evaluating each test across
the large collective cohort using the same validation
procedure, we compared the power of the genetic
variants to evaluate classification performance. The
performance of the three-SNP panel described by
Jakobsdottir and colleagues41 revealed an AUC value
of 0.77, compared with a value of 0.79 observed in
the original study of 642 late-stage AMD cases and
142 controls. The differences in AUC values
obtained between the original and the current study
are likely to reflect the impact of testing across a
large collection of independently collected cohorts
compared with a single study that is potentially
more sensitive to subject selection bias. The per-
formance of the six-SNP test panel reported by
Seddon and colleagues42 as part of a joint gene–
environment model exhibited a drop in AUC from
0.81 to 0.79 from training to validation in our data
(significant at P , 0.05), similar to most of the tests
evaluated. This decrease in AUC reveals the value of
the inclusion of an independent validation set to
challenge test performance and estimate metrics
achievable in the broader clinical setting more accu-
rately. We have emphasised the importance of both
study design features to report performance more
accurately and to anticipate utility in the more
diverse clinical testing market more closely. Finally,
modest gains in our 13-SNP panel were demon-
strated with the highest AUC value obtained among
all models evaluated (0.80). The additional variants
that contributed to the performance of the predic-
tive test located in CFHR5 and F13B highlight the
complexity of the genetic structure of the RCA
region and influence AMD disease biology.
In summary, the 13-SNP panel had a clinical
sensitivity of 82 per cent and a specificity of 63
per cent, achieving clinical performance metrics
comparable with models with fewer SNPs that
include self-reported and/or non-static risk factors.
The PPV of the panel was evaluated at different
levels of prevalence, reflecting ranges covering
estimates of late-stage disease in individuals . 40,
. 65 and . 80 years of age in the general popu-
lation. More favourable estimates of PPV were





















0.79 0.77 ,0.0001 0.77 ,0.001
Six-SNP
(Seddon42)
0.82a 0.81 ,0.01 0.79 ,0.05
Nine-SNP
(SCMM)
NA 0.81 ,0.01 0.79 nsb
13-SNP
(SCMM)
NA 0.82 — 0.80 —
AUC, area under the curve; SCMM, Sequenom Center for Molecular Medicine.
aAUC value based on model with six SNPs and multiple environmental risk variables (eg baseline grade, education status, BMI, smoking history).
bns: not significant (p . 0.05).
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observed as the prevalence of disease increases with
age. The values obtained revealed 11 per cent PPV
at 5.5 per cent prevalence, 20 per cent PPV at 10
per cent prevalence and 28 per cent PPV at 15 per
cent prevalence in the general population.41 The
prevalence figures reflect conservative estimates of
late-stage disease in the general population and
would be further enhanced and more clinically appli-
cable in a setting of diseased patients, as in the study
conducted by Seddon and colleagues.42 The longi-
tudinal study design of the Age-Related Eye Disease
Study (AREDS) cohort used in Seddon’s study was
ideal for evaluating incident AMD by distinguishing
between ‘progressors’ and ‘non-progressors’ but,
more importantly, it established that the same set of
variants were effective at distinguishing non-disease
controls from patients with late-stage disease. Not
surprisingly, the same core panel of SNPs covering
the major genes associated with disease used in
Seddon and co-workers’ test panel was also utilised
in the study conducted by Jakobsdottir and col-
leagues,41 as well as in our current study.
The present confirmatory findings reflect the
utility of these variants to predict the development of
CNV in non-diseased subjects in our study, as well
as the progression to late-stage disease in patients
diagnosed with early forms of AMD.42 PPVs
improve significantly when applied to the population
of patients diagnosed with early stages of disease.
The utility of AMD genetic testing will advance if
the result of a predictive test translates into actionable
information for the physician. This study highlights
the need to continue to explore the biology of CNV,
to improve our understanding of the genetics associ-
ated with disease and extend these findings in future
studies to evaluate clinical performance metrics in
the more acute clinical population diagnosed with
early-stage disease. A genetic test identifying individ-
uals at high risk of developing CNV holds the
promise for earlier detection through risk-based sur-
veillance protocols and improved outcomes arising
from more timely intervention.
Acknowledgments
The authors wish to thank Karsten Schmidt, Ronald Lindsay,
Lindsay Farrer, Margo Maeder, and members of the Guymer
(Melinda Cain, Khin Zaw Aung, Andrea Richardson),
Hageman (Chris Pappas, David Hutchesen, Eric Brown, Jill
Hageman, Lucia Lucci, William Hubbard), Allikmets
(Johanna Merriam), and DeAngelis laboratories (Margaux
Morrison, Denise Jones) for their contributions to this study.
This study was funded by NIH R24-EY017404 (GSH),
EY014458 (MD), EY13435 (RA), EY017404 (RA), the
NHMRC Centre for Clinical Research Excellence from the
National Health and Medical Research (NHMRC #529923;
RG), the Macula Vision Research Foundation, the Kaplen
Foundation and unrestricted grants to the Department of
Ophthalmology, Columbia University and the John A. Moran
Eye Center, University of Utah from Research to Prevent
Blindness, Inc.
References
1. Rein, D.B., Wittenborn, J.S., Zhang, X. et al. (2009), ‘Forecasting
age-related macular degeneration through the year 2050: The potential
impact of new treatment’, Arch. Ophthalmol. Vol. 127, pp. 533–540.
2. Brown, G.C., Brown, M.M., Sharma, S. et al. (2006), ‘The burden of
age-related macular degeneration: A value-based medicine analysis’, Trans.
Am. Ophthalmolol. Soc. Vol. 103, pp. 173–186.
3. Klein, R., Klein, B.E.K., Jensen, S.C. and Meuer, S.M. (1997), ‘The
5-year incidence and progression of age-related maculopathy. The Beaver
Dam Eye Study’, Ophthalmology Vol. 104, pp. 7–21.
4. Klein, R., Peto, T., Bird, A. and Vannewkirk, M.R. (2004), ‘The epide-
miology of age-related macular degeneration’, Am. J. Ophthalmol. Vol.
137, pp. 486–495.
5. Allikmets, R. and Dean, M. (2008), ‘Bringing age-related macular
degeneration into focus’, Nat. Genet. Vol. 40, pp. 820–821.
6. Swaroop, A., Chew, E.Y., Rickman, C.B. and Abecasis, G.R. (2009),
‘Unraveling a multifactorial late-onset disease: From genetic susceptibility
to disease mechanisms for age-related macular degeneration’, Annu. Rev.
Genomics Hum. Genet. Vol. 10, pp. 19–43.
7. Connell, P.P., Keane, P.A., O’Neill, E.C. et al. (2009), ‘Risk factors for
age-related maculopathy’, J. Ophthalmol. Vol. 2009, Article ID 360764.
8. Scott, W.K., Schmidt, S., Hauser, M.A. et al. (2007), ‘Independent
effects of complement factor H Y402H polymorphism and cigarette
smoking on risk of age-related macular degeneration’, Ophthalmology Vol.
114, pp. 1151–1156.
9. DeAngelis, M.M., Ji, F., Kim, I.K. et al. (2007), ‘Cigarette smoking,
CFH, APOE, ELOVL4, and risk of neovascular age-related macular
degeneration’, Arch. Ophthalmol. Vol. 125, pp. 49–54.
10. DeAngelis, M.M., Ji, F., Adams, S. et al. (2008), ‘Alleles in the HtrA
serine peptidase 1 gene alter the risk of neovascular age-related macular
degeneration’, Ophthalmology Vol. 115, pp. 1209–1215.e7.
11. Dewan, A., Liu, M., Hartman, S. et al. (2006), ‘HTRA1 promoter poly-
morphism in wet age-related macular degeneration’, Science Vol. 314,
pp. 989–992.
12. Edwards, A.O., Ritter, R., 3rd, Abel, K.J. et al. (2005), ‘Complement
factor H polymorphism and age-related macular degeneration’, Science
Vol. 308, pp. 421–424.
13. Hageman, G.S., Anderson, D.H., Johnson, L.V. et al. (2005), ‘A common
haplotype in the complement regulatory gene factor H (HF1/CFH) pre-
disposes individuals to age-related macular degeneration’, Proc. Natl.
Acad. Sci. USAVol. 102, pp. 7227–7232.
14. Haines, J.L., Hauser, M.A., Schmidt, S. et al. (2005), ‘Complement
factor H variant increases the risk of age-related macular degeneration’,
Science Vol. 308, pp. 419–421.
15. Jakobsdottir, J., Conley, Y.P., Weeks, D.E. et al. (2005), ‘Susceptibility
genes for age-related maculopathy on chromosome 10q26’, Am. J. Hum.
Genet. Vol. 77, pp. 389–407.
PRIMARY RESEARCH Hageman et al.
434 # HENRY STEWART PUBLICATIONS 1479–7364. HUMAN GENOMICS. VOL 5. NO 5. 420–440 JULY 2011
16. Klein, R.J., Zeiss, C., Chew, E.Y. et al. (2005), ‘Complement factor H
polymorphism in age-related macular degeneration’, Science Vol. 308,
pp. 385–389.
17. Li, M., Atmaca-Sonmez, P., Othman, M. et al. (2006), ‘CFH haplotypes
without the Y402H coding variant show strong association with suscep-
tibility to age-related macular degeneration’, Nat. Genet. Vol. 38,
pp. 1049–1054.
18. Rivera, A., Fisher, S.A., Fritsche, L.G. et al. (2005), ‘Hypothetical
LOC387715 is a second major susceptibility gene for age-related macular
degeneration, contributing independently of complement factor H to
disease risk’, Hum. Mol. Genet. Vol. 14, pp. 3227–3236.
19. Yang, Z., Camp, N.J., Sun, H. et al. (2006), ‘A variant of the HTRA1
gene increases susceptibility to age-related macular degeneration’, Science
Vol. 314, pp. 992–993.
20. Anderson, D.H., Mullins, R.F., Hageman, G.S. and Johnson, L.V. (2002),
‘A role for local inflammation in the formation of drusen in the aging
eye’, Am. J. Ophthalmol. Vol. 134, pp. 411–431.
21. Anderson, D.H., Radeke, M.J., Gallo, N.B. et al. (2010), ‘The pivotal
role of the complement system in aging and age-related macular degener-
ation: hypothesis re-visited’, Prog. Retin. Eye Res. Vol. 29, pp. 95–112.
22. Gehrs, K.M., Anderson, D.H., Johnson, L.V. and Hageman, G.S. (2006),
‘Age-related macular degeneration — Emerging pathogenetic and thera-
peutic concepts’, Ann. Med. Vol. 38, pp. 450–471.
23. Gehrs, K.M., Jackson, J.R., Brown, E.N. et al. (2010), ‘Complement,
age-related macular degeneration and a vision for the future’, Arch.
Ophthalmol. Vol. 128, pp. 349–358.
24. Hageman, G.S., Mullins, R.F., Russell, S.R. et al. (1999), ‘Vitronectin is
a constituent of ocular drusen and the vitronectin gene is expressed in
human retinal pigmented epithelial cells’, FASEB J. Vol. 13, pp.
477–484.
25. Hageman, G.S., Luthert, P.J., Victor Chong, N.H. et al. (2001), ‘An inte-
grated hypothesis that considers drusen as biomarkers of immune-
mediated processes at the RPE-Bruch’s membrane interface in aging and
age-related macular degeneration’, Prog. Retin. Eye Res. Vol. 20, pp.
705–732.
26. Mullins, R.F., Russell, S.R., Anderson, D.H. and Hageman, G.S. (2000),
‘Drusen associated with aging and age-related macular degeneration
contain proteins common to extracellular deposits associated with athero-
sclerosis, elastosis, amyloidosis, and dense deposit disease’, FASEB J. Vol.
14, pp. 835–846.
27. Ennis, S., Gibson, J., Cree, A.J. et al. (2010), ‘Support for the involve-
ment of complement factor I in age-related macular degeneration’,
Eur. J. Hum. Genet. Vol. 18, pp. 15–16.
28. Fagerness, J.A., Maller, J.B., Neale, B.M. et al. (2009), ‘Variation near
complement factor I is associated with risk of advanced AMD’,
Eur. J. Hum. Genet. Vol. 17, pp. 100–104.
29. Gold, B., Merriam, J.E., Zernant, J. et al. (2006), ‘Variation in factor B
(BF) and complement component 2 (C2) genes is associated with
age-related macular degeneration’, Nat. Genet. Vol. 38, pp. 458–462.
30. Hageman, G.S., Hancox, L.S., Taiber, A.J. et al. (2006), ‘Extended hap-
lotypes in the complement factor H (CFH) and CFH-related (CFHR)
family of genes protect against age-related macular degeneration:
Characterization, ethnic distribution and evolutionary implications’, Ann.
Med. Vol. 38, pp. 592–604.
31. Hughes, A.E., Orr, N., Esfandiary, H. et al. (2006), ‘A common CFH
haplotype, with deletion of CFHR1 and CFHR3, is associated with
lower risk of age-related macular degeneration’, Nat. Genet. Vol. 38, pp.
1173–1177.
32. Jakobsdottir, J., Conley, Y.P., Weeks, D.E. et al. (2008), ‘C2 and CFB
genes in age-related maculopathy and joint action with CFH and
LOC387715 genes’, PLoS. ONE Vol. 3, p. e2199.
33. Kondo, N., Bessho, H., Honda, S. and Negi, A. (2010), ‘Additional evi-
dence to support the role of a common variant near the complement
factor I gene in susceptibility to age-related macular degeneration’,
Eur. J. Hum. Genet. Vol. 18, pp. 634–635.
34. Maller, J., George, S., Purcell, S. et al. (2006), ‘Common variation in
three genes, including a noncoding variant in CFH, strongly influences
risk of age-related macular degeneration’, Nat. Genet. Vol. 38, pp.
1055–1059.
35. Maller, J.B., Fagerness, J.A., Reynolds, R.C. et al. (2007), ‘Variation in
complement factor 3 is associated with risk of age-related macular
degeneration’, Nat. Genet. Vol. 39, pp. 1200–1201.
36. Spencer, K.L., Olson, L.M., Anderson, B.M. et al. (2008), ‘C3 R102G
polymorphism increases risk of age-related macular degeneration’, Hum.
Mol. Genet. Vol. 17, pp. 1821–1824.
37. Yates, J.R., Sepp, T., Matharu, B.K. et al. (2007), ‘Complement C3
variant and the risk of age-related macular degeneration’,
N. Engl. J. Med. Vol. 357, pp. 553–561.
38. Zhang, H., Morrison, M.A., Dewan, A. et al. (2008), ‘The NEI/NCBI
dbGAP database: Genotypes and haplotypes that may specifically predis-
pose to risk of neovascular age-related macular degeneration’, BMC Med.
Genet. Vol. 9, p. 51.
39. Chen, W., Stambolian, D., Edwards, A.O. et al. (2010), ‘Genetic variants
near TIMP3 and high-density lipoprotein-associated loci influence sus-
ceptibility to age-related macular degeneration’, Proc. Natl. Acad. Sci.
USAVol. 107, pp. 7401–7406.
40. Neale, B.M., Fagerness, J., Reynolds, R. et al. (2010), ‘Genome-wide
association study of advanced age-related macular degeneration identifies
a role of the hepatic lipase gene (LIPC)’, Proc. Natl. Acad. Sci. USA Vol.
107, pp. 7395–7400.
41. Jakobsdottir, J., Gorin, M.B., Conley, Y.P. et al. (2009), ‘Interpretation
of genetic association studies: markers with replicated highly signifi-
cant odds ratios may be poor classifiers’, PLoS Genet. Vol. 5,
p. e1000337.
42. Seddon, J.M., Reynolds, R., Maller, J. et al. (2009), ‘Prediction model
for prevalence and incidence of advanced age-related macular degener-
ation based on genetic, demographic, and environmental variables’,
Invest. Ophthalmol. Vis. Sci. Vol. 50, pp. 2044–2053.
43. McKay, G.J., Dasari, S., Patterson, C.C. et al. (2010), ‘Complement com-
ponent 3: An assessment of association with AMD and analysis of gene-
gene and gene-environment interactions in a Northern Irish cohort’,
Mol. Vis. Vol. 16, pp. 194–199.
44. Zanke, B., Hawken, S., Carter, R. and Chow, D. (2010), ‘A genetic
approach to stratification of risk for age-related macular degeneration’,
Can. J. Ophthalmol. Vol. 45, pp. 22–27.
45. Brown, E.N., Hancox, L.S., Miller, N.J. et al. (2010), ‘Determination
and assessment of extended haplotypes spanning the chromosome 1q32
CFH-to-CFHR5 locus’, Invest. Ophthalmol. Vis. Sci. Vol. 51, Abstract
1262.
46. Baird, P.N., Islam, F.M., Richardson, A.J. et al. (2006), ‘Analysis of the
Y402H variant of the complement factor H gene in age-related macular
degeneration’, Invest. Ophthalmol. Vis. Sci. Vol. 47, pp. 4194–4198.
47. Robman, L., Baird, P.N., Dimitrov, P.N. et al. (2010), ‘C-reactive protein
levels and complement factor H polymorphism interaction in age-related
macular degeneration and its progression’, Ophthalmology Vol. 117, pp.
1982–1988.
48. National Center for Biotechnology Information, National Library of
Medicine Database of Single Nucleotide Polymorphisms (dbSNP).
http://www.ncbi.nlm.nih.gov/SNP. (Accessed 4th April, 2011).
49. Kent, W.J., Sugnet, C.W., Furey, T.S. et al. (2002), ‘The human genome
browser at UCSC’, Genome Res. Vol. 12, pp. 996–1006.
50. Ambroise, C. and McLachlan, G. (2002), ‘Selection bias in gene extrac-
tion on the basis of microarray gene-expression data’, Proc. Natl. Acad.
Sci. USAVol. 99, pp. 6562–6566.
51. DeLong, E.R., DeLong, D.M. and Clarke-Pearson, D.L. (1988),
‘Comparing the areas under two or more correlated receiver operating
characteristic curves: a nonparametric approach’, Biometrics Vol. 44, pp.
837–845.
52. SAS Institute Inc. (2008), ‘SAS Version 9.1’, SAS Institute, Cary, NC,
USA.
53. Rosner, B. and Glynn, R.J. (2009), ‘Power and sample size estimation
for the Wilcoxon rank sum test with application to comparisons of C
statistics from alternative prediction models’, Biometrics Vol. 65,
pp. 188–197.
Clinical validation of a genetic model PRIMARY RESEARCH
# HENRY STEWART PUBLICATIONS 1479–7364. HUMAN GENOMICS. VOL 5. NO 5. 420–440 JULY 2011 435





Number of response levels 2
Model Binary logit
Optimisation technique Fisher’s scoring
Number of observations read 1,000
Number of observations used 949
Response profile
Ordered value Response Total frequency
1 0 467
2 1 482
Probability modelled is response ¼ 0.
Note: 51 observations were deleted due to missing values for the response or
explanatory variables.
Backward elimination procedure
Step 0. The following effects were entered:
Intercept rs10490924 rs1061170 rs10922153
rs12144939 rs1409153 rs1750311 rs2230199
rs2274700 rs2990510 rs403846 rs641153 rs698859
rs9332739
Model convergence status
Convergence criterion (GCONV ¼ 1E-8) satisfied.
Model fit statistics
Criterion Intercept only Intercept and covariates
AIC 1317.356 1016.228
SC 1322.212 1084.204
–2 Log L 1315.356 988.228
Testing global null hypothesis: BETA 5 0
Test Chi-square DF Pr > ChiSq
Likelihood ratio 327.1278 13 ,0.0001
Continued
Continued
Testing global null hypothesis: BETA 5 0
Test Chi-square DF Pr > ChiSq
Score 280.8660 13 ,0.0001
Wald 209.1689 13 ,0.0001
Step 1. Effect rs698859 is removed:
Model convergence status
Convergence criterion (GCONV ¼ 1E-8) satisfied.
Model Fit Statistics
Criterion Intercept only Intercept and covariates
AIC 1317.356 1014.231
SC 1322.212 1077.352
–2 Log L 1315.356 988.231
Testing global null hypothesis: BETA 5 0
Test Chi-square DF Pr > ChiSq
Likelihood ratio 327.1248 12 ,0.0001
Score 280.8660 12 ,0.0001
Wald 209.1627 12 ,0.0001
Residual Chi-square test
Chi-Square DF Pr > ChiSq
0.0031 1 0.9559
Step 2. Effect rs1409153 is removed:
Model convergence status
Convergence criterion (GCONV ¼ 1E-8) satisfied.
Model fit statistics
Criterion Intercept only Intercept and covariates
AIC 1317.356 1012.567
SC 1322.212 1070.832
–2 Log L 1315.356 988.567
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Testing global null hypothesis: BETA 5 0
Test Chi-square DF Pr > ChiSq
Likelihood ratio 326.7893 11 ,0.0001
Score 280.6633 11 ,0.0001
Wald 209.0053 11 ,0.0001
Residual Chi-square test
Chi-square DF Pr > ChiSq
0.3389 2 0.8441
Step 3. Effect rs1750311 is removed:
Model convergence status
Convergence criterion (GCONV ¼ 1E-8) satisfied.
Model fit statistics
Criterion Intercept only Intercept and covariates
AIC 1317.356 1010.949
SC 1322.212 1064.358
–2 Log L 1315.356 988.949
Testing global null hypothesis: BETA 5 0
Test Chi-square DF Pr > ChiSq
Likelihood ratio 326.4077 10 ,0.0001
Score 280.4794 10 ,0.0001
Wald 209.1743 10 ,0.0001
Residual Chi-square test
Chi-Square DF Pr > ChiSq
0.7200 3 0.8685
Step 4. Effect rs12144939 is removed:
Model convergence status
Convergence criterion (GCONV ¼ 1E-8) satisfied.
Model fit statistics
Criterion Intercept only Intercept and covariates
AIC 1317.356 1010.903
SC 1322.212 1059.457
22 Log L 1315.356 990.903
Testing global null hypothesis: BETA 5 0
Test Chi-square DF Pr > ChiSq
Likelihood ratio 324.4536 9 ,0.0001
Score 279.2738 9 ,0.0001
Wald 209.2428 9 ,0.0001
Residual Chi-square test
Chi-square DF Pr > ChiSq
2.6773 4 0.6132
Note: No (additional) effects met the 0.05 significance level for removal from the
model.







Chi-square Pr > ChiSq
1 rs698859 1 12 0.0031 0.9559
2 rs1409153 1 11 0.3356 0.5624
3 rs1750311 1 10 0.3820 0.5366
4 rs12144939 1 9 1.9468 0.1629









Intercept 1 20.7554 0.2621 8.3051 0.0040
rs10490924 1 21.4417 0.1245 134.0342 ,0.0001
rs1061170 1 0.7697 0.2988 6.6352 0.0100
rs10922153 1 0.7240 0.1950 13.7839 0.0002
rs2230199 1 20.4292 0.1286 11.1389 0.0008
rs2274700 1 0.8593 0.1695 25.7009 ,0.0001
Continued
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rs2990510 1 0.4556 0.1586 8.2557 0.0041
rs403846 1 20.6775 0.3341 4.1118 0.0426
rs641153 1 0.8243 0.1999 17.0040 ,0.0001








rs10490924 0.237 0.185 0.302
rs1061170 2.159 1.202 3.878
rs10922153 2.063 1.407 3.023










rs2274700 2.362 1.694 3.292
rs2990510 1.577 1.156 2.152
rs403846 0.508 0.264 0.978
rs641153 2.280 1.541 3.374
rs9332739 2.588 1.392 4.811
Association of predicted probabilities and observed
responses
Percentage concordant 81.5 Somers’ D 0.637
Percentage discordant 17.9 Gamma 0.641
Percentage tied 0.6 Tau-a 0.319














0.000 467 0 482 0 49.2 100.0 0.0 50.8 —
0.020 467 3 479 0 49.5 100.0 0.6 50.6 0.0
0.040 467 20 462 0 51.3 100.0 4.1 49.7 0.0
0.060 467 35 447 0 52.9 100.0 7.3 48.9 0.0
0.080 467 49 433 0 54.4 100.0 10.2 48.1 0.0
0.100 465 65 417 2 55.8 99.6 13.5 47.3 3.0
0.120 461 91 391 6 58.2 98.7 18.9 45.9 6.2
0.140 457 113 369 10 60.1 97.9 23.4 44.7 8.1
0.160 450 143 339 17 62.5 96.4 29.7 43.0 10.6
0.180 448 159 323 19 64.0 95.9 33.0 41.9 10.7
Continued
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0.200 442 182 300 25 65.8 94.6 37.8 40.4 12.1
0.220 438 200 282 29 67.2 93.8 41.5 39.2 12.7
0.240 435 213 269 32 68.3 93.1 44.2 38.2 13.1
0.260 434 217 265 33 68.6 92.9 45.0 37.9 13.2
0.280 423 227 255 44 68.5 90.6 47.1 37.6 16.2
0.300 422 246 236 45 70.4 90.4 51.0 35.9 15.5
0.320 419 252 230 48 70.7 89.7 52.3 35.4 16.0
0.340 414 271 211 53 72.2 88.7 56.2 33.8 16.4
0.360 410 274 208 57 72.1 87.8 56.8 33.7 17.2
0.380 389 287 195 78 71.2 83.3 59.5 33.4 21.4
0.400 385 303 179 82 72.5 82.4 62.9 31.7 21.3
0.420 381 312 170 86 73.0 81.6 64.7 30.9 21.6
0.440 365 326 156 102 72.8 78.2 67.6 29.9 23.8
0.460 361 331 151 106 72.9 77.3 68.7 29.5 24.3
0.480 358 340 142 109 73.6 76.7 70.5 28.4 24.3
0.500 344 354 128 123 73.6 73.7 73.4 27.1 25.8
0.520 332 357 125 135 72.6 71.1 74.1 27.4 27.4
0.540 324 366 116 143 72.7 69.4 75.9 26.4 28.1
0.560 315 378 104 152 73.0 67.5 78.4 24.8 28.7
0.580 300 389 93 167 72.6 64.2 80.7 23.7 30.0
0.600 293 392 90 174 72.2 62.7 81.3 23.5 30.7
0.620 284 398 84 183 71.9 60.8 82.6 22.8 31.5
0.640 266 410 72 201 71.2 57.0 85.1 21.3 32.9
0.660 252 417 65 215 70.5 54.0 86.5 20.5 34.0
0.680 236 423 59 231 69.4 50.5 87.8 20.0 35.3
0.700 233 427 55 234 69.5 49.9 88.6 19.1 35.4
0.720 196 440 42 271 67.0 42.0 91.3 17.6 38.1
0.740 190 441 41 277 66.5 40.7 91.5 17.7 38.6
0.760 179 448 34 288 66.1 38.3 92.9 16.0 39.1
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0.780 170 453 29 297 65.6 36.4 94.0 14.6 39.6
0.800 127 456 26 340 61.4 27.2 94.6 17.0 42.7
0.820 114 467 15 353 61.2 24.4 96.9 11.6 43.0
0.840 103 467 15 364 60.1 22.1 96.9 12.7 43.8
0.860 77 470 12 390 57.6 16.5 97.5 13.5 45.3
0.880 65 471 11 402 56.5 13.9 97.7 14.5 46.0
0.900 53 475 7 414 55.6 11.3 98.5 11.7 46.6
0.920 40 479 3 427 54.7 8.6 99.4 7.0 47.1
0.940 16 481 1 451 52.4 3.4 99.8 5.9 48.4
0.960 9 481 1 458 51.6 1.9 99.8 10.0 48.8
0.980 1 481 1 466 50.8 0.2 99.8 50.0 49.2
1.000 0 482 0 467 50.8 0.0 100.0 — 49.2
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